Abbott Norvir Pricing Investigation Urged In Senate Letter To FTC
Abbott's price increase for Norvir should be investigated by the Federal Trade Commission, three senators said
You may also be interested in...
An NIH public hearing on Abbott's Norvir will address whether the federal government should use "march-in" authorities to grant compulsory licensing of Norvir patents
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials